A Multi-Institutional Retrospective Analysis of Tyrosine Kinase Inhibitor (TKI) Clinical and Preclinical Efficacy According to BCR-ABL Mutation Status in CP-CML Patients
Year: 2015
Type: article
Study design: Observational Study
Source: Blood
Authors: Victor M. Rivera, Susan Branford, Franck E. Nicolini, Justin R. Pritchard, Joseph M. Gozgit, Wolfgang Kern, Dragana Milojkovic, Simone Claudiani, Martin C. Muller, Srinivas K Tantravahi, Michael W. Deininger, Michael Heinrich, Simona Soverini, Michele Baccarani, Jerald P. Radich, Elias Jabbour, Jorge E. Cortes, Gabriel Etienne, Torsten Haferlach
Institutions: ARIAD Pharmaceuticals (United States), South Australia Pathology, University of South Australia, Centre for Cancer Biology, The University of Adelaide, Inserm, Hôpital Lyon Sud, Munich Leukemia Laboratory (Germany), Imperial College Healthcare NHS Trust, Hammersmith Hospital, University Medical Centre Mannheim, University of Utah, Huntsman Cancer Institute, OHSU Knight Cancer Institute, IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, University of Bologna, Fred Hutch Cancer Center, The University of Texas MD Anderson Cancer Center, Institut Bergonié
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2980008529